TrialPharmacology research & perspectives2026

Pharmacokinetic, Safety, and Immunogenicity Similarity of High- and Low-Concentration Formulations of Adalimumab Biosimilar ABP 501, Adalimumab-Atto.

Vincent Chow et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.